Vaxcyte Cash Flow Statement Analysis

Operating, investing, and financing activities in billions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Vaxcyte, Inc. (PCVX) - Annual data in billions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-0.46-0.40-0.22-0.10-0.09
Depreciation & Amortization0.020.010.010.000.00
Stock Based Compensation0.080.050.020.010.01
Change in Working Capital-0.050.030.01-0.040.04
Change in Accounts Payable0.030.010.00-0.010.03
Change in Other Working Capital-0.04-0.030.01-0.020.01
Other Operating Activities-0.040.060.01-0.010.00
Net Cash from Operating Activities-0.45-0.30-0.17-0.12-0.05
Investing Activities
Capital Expenditures-0.120.02-0.01-0.010.00
Purchases of Investments-3.09-1.330.08-0.210.00
Sales/Maturities of Investments1.20-0.050.18-0.210.00
Other Investing Activities-0.10-0.050.000.000.00
Net Cash from Investing Activities-2.01-0.770.07-0.210.00
Financing Activities
Common Stock Issued2.440.640.860.020.27
Other Financing Activities-0.010.000.000.000.00
Net Cash from Financing Activities2.450.640.860.020.37
Summary
Effect of Forex Changes on Cash0.00-0.010.000.000.00
Net Change in Cash-0.01-0.440.77-0.320.33
Cash at Beginning of Period0.400.840.070.390.06
Cash at End of Period0.39-0.360.840.070.39
Free Cash Flow-0.57-0.31-0.18-0.13-0.05
Supplemental Disclosures
Interest Paid0.000.000.000.000.00